Nvwm LLC Has $86,000 Stock Holdings in Merck & Co., Inc. $MRK

Nvwm LLC grew its holdings in Merck & Co., Inc. (NYSE:MRK) by 137.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,082 shares of the company’s stock after purchasing an additional 627 shares during the period. Nvwm LLC’s holdings in Merck & Co., Inc. were worth $86,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of MRK. Peoples Financial Services CORP. increased its position in Merck & Co., Inc. by 0.5% during the 2nd quarter. Peoples Financial Services CORP. now owns 22,778 shares of the company’s stock worth $1,803,000 after purchasing an additional 122 shares in the last quarter. McLean Asset Management Corp boosted its position in Merck & Co., Inc. by 3.7% in the second quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock valued at $292,000 after buying an additional 125 shares in the last quarter. Cora Capital Advisors LLC grew its stake in shares of Merck & Co., Inc. by 2.4% during the second quarter. Cora Capital Advisors LLC now owns 5,343 shares of the company’s stock worth $423,000 after buying an additional 125 shares during the last quarter. Saiph Capital LLC increased its holdings in shares of Merck & Co., Inc. by 3.7% during the first quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock worth $320,000 after buying an additional 128 shares in the last quarter. Finally, Physician Wealth Advisors Inc. grew its holdings in shares of Merck & Co., Inc. by 2.9% during the second quarter. Physician Wealth Advisors Inc. now owns 4,587 shares of the company’s stock worth $363,000 after purchasing an additional 128 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $86.34 on Friday. The firm has a market capitalization of $215.66 billion, a P/E ratio of 13.30, a P/E/G ratio of 0.95 and a beta of 0.34. The firm’s 50-day moving average price is $84.59 and its 200-day moving average price is $82.04. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $105.07.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, October 30th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.36 by $0.22. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The company had revenue of $17.28 billion during the quarter, compared to the consensus estimate of $17 billion. During the same period last year, the business posted $1.57 EPS. The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MRK has been the topic of several analyst reports. Berenberg Bank cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a report on Saturday. Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Wednesday, October 8th. Wells Fargo & Company lowered their price target on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, July 30th. Finally, Citigroup assumed coverage on shares of Merck & Co., Inc. in a research note on Monday, October 13th. They set a “neutral” rating and a $95.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $104.47.

Insider Activity

In related news, EVP David Michael Williams sold 8,614 shares of Merck & Co., Inc. stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $83.59, for a total value of $720,044.26. Following the completion of the sale, the executive vice president owned 24,578 shares of the company’s stock, valued at approximately $2,054,475.02. This trade represents a 25.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.